Experimentally imposed calorie restriction (CR) is shown to result in the most reproducible endpoint of lifespan extension in all animals models tested. In this presentation, the question of CR's effect on human longevity is reviewed by discussing data pertinent to the putative efficacy of CR on humans. Arguments are presented in support of this possibility based on CR's unique abilities to retard biological functional declines and to deter pathological processes, both of which are major targets of deleterious oxidative stress.
Caloric (or dietary) restriction (CR) extends lifespan and lowers risk for age associated diseases in a phylogenetically diverse group of species. Whether prolonged CR increases average or maximum lifespan or promotes a more youthful physiology in humans at advanced ages is not yet known. However, available epidemiological evidence indicates that CR may already have contributed to an extension of average and maximum life span in one human population and appears to have lowered risk for age associated chronic diseases in other human populations.
Medical Decision Making: An International Journal of the Society for Medical Decision Making
BACKGROUND: Although congestive heart failure (CHF) is a primary target for disease management programs, previous studies have generated mixed results regarding the effectiveness and cost savings of disease management when applied to CHF. OBJECTIVE: We estimated the long-term impact of systolic heart failure disease management from the results of an 18-month clinical trial.
Romanian Journal of Internal Medicine = Revue Roumaine De MÈdecine Interne
Decreased high density lipoproteins (HDL) plasma levels are a recognized independent risk factor for atherosclerotic cardiovascular disease. Attempts were therefore initiated to pharmacologically raise plasma HDL cholesterol, and the most impressive increase was obtained by inhibiting cholesteryl ester transfer protein (CETP) by means of the synthetic compound torcetrapib. Clinical trials were however disappointing, as torcetrapib increased mortality and did not reduce the progression of atherosclerosis.
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences
The author focused on the functional decline of synapses in the brain with aging to understand the underlying mechanisms and to ameliorate the deficits. The first attempt was to unravel the neuronal functions of gangliosides so that gangliosides could be used for enhancing synaptic activity. The second attempt was to elicit the neuronal plasticity in aged animals through enriched environmental stimulation and nutritional intervention. Environmental stimuli were revealed neurochemically and morphologically to develop synapses leading to enhanced cognitive function.
Calorie restriction (CR), or a diet modification aiming to reduce the total intake of calories by 20%-40%, has been shown to increase longevity across multiple species. Recently, there has been growing interest in investigating the potential role of CR as a treatment intervention for age-related diseases, such as cancer, because an increasing body of literature has demonstrated a metabolic component to both carcinogenesis and tumor progression. In fact, many of the molecular pathways that are altered with CR are also known to be altered in cancer.
BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Systemic lupus erythematosus (SLE) is a complex heterogeneous disease, posing challenges to clinical trials. As in other autoimmune diseases, B-lymphocytes play a central role in lupus pathogenesis. The finding that selection and survival of B cells are controlled by a variety of signals, including those provided by the longevity factor BAFF (B-cell activating factor), also called BLyS (B-lymphocyte stimulator), led to preclinical trials that revealed that BAFF represents a promising therapeutic target for human lupus. Belimumab is a fully human monoclonal antibody directed against BAFF.
The scientific foundations for risk factor modification in the elderly are three-fold: (1) data from long-term prospective population studies demonstrating significant independent relationships between established major risk factors--particularly blood pressure (systolic and diastolic), serum cholesterol, cigarette use, clinical diabetes--and risk of cardiovascular (CV) morbidity and mortality; (2) data from population studies on time trends of mass changes in major risk factors and parallel changes in CV mortality rates, including large sustained declines; (3) data from randomized controll
Lipoproteins and the impact of lipid lowering on progression and regression of coronary artery disease are discussed. Angiographically assessed regression studies are reviewed (NHLBI, LIT, LHT, CLAS I and II, FATS, POSCH, Heidelberg, STARS, SCRIP, MAAS, PLAC I, HARP, UC-SF), as are B-mode ultrasound studies (ACAPS, PLAC II) and survival studies (Oslo diet-smoking study, SSSS, Pravastatin, Oxford). Although study populations and the interventions are different in the studies, I have come to the following conclusions.